GPCR/G protein
All GPCRs share a common seven trans-membrane structure. GPCRs are associated with heterotrimeric G-proteins which are GTP-binding proteins made of alpha, beta, and gamma subunits. When a ligand binds to GPCR, it activates the attached G-protein, the GDP is replaced with GTP. The activated G-protein then dissociates into an alpha and a beta-gamma complex which activates downstream signaling pathways. These intracellular signaling pathways include cAMP/PKA, calcium/NFAT, phospholipase C, protein tyrosine kinases, MAP kinases, PI-3-kinase, nitric oxide/cGMP, Rho, and JAK/STAT.
GPCRs are one of the most important therapeutic targets for various diseases, over 30% of all modern medicinal drugs target this family. Aberrant GPCR functions are involved in pathological conditions such as neurological, immunological and hormonal disorders. A large number of GPCRs have been identified, but whose ligands are not known, are classified as orphan receptors.
- A3179 AnamorelinSummary: Ghrelin receptor agonist, synthetic, orally active
- A3192 Asenapine hydrochlorideSummary: Atypical antipsychotic
- A3201 Atrasentan hydrochlorideSummary: Endothelin receptor antagonist
- A3208 AvosentanSummary: ETA receptor antagonist
- A3219 BAN ORL 24Summary: NOP receptor antagonist, potent and selective
- A3241 BilobalideSummary: Neuroprotective agent
- A3275 Calcium-Sensing Receptor Antagonists ISummary: CaSR antagonist
- A3277 CapadenosonSummary: Adenosine A1 receptor agonist
- A3289 CCG-63802Summary: RGS protein inhibitor
- A3290 CCG-63808Summary: Reversible RGS inhibitor